Zevra Therapeutics, Inc. (ZVRA)
- Previous Close
4.5200 - Open
4.5200 - Bid 4.5100 x 100
- Ask 4.5400 x 200
- Day's Range
4.4800 - 4.6000 - 52 Week Range
3.8900 - 7.2800 - Volume
155,948 - Avg. Volume
250,861 - Market Cap (intraday)
189.164M - Beta (5Y Monthly) 1.84
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3000 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.00
Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
zevra.comRecent News: ZVRA
Performance Overview: ZVRA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZVRA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZVRA
Valuation Measures
Market Cap
189.16M
Enterprise Value
165.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.84
Price/Book (mrq)
3.06
Enterprise Value/Revenue
6.02
Enterprise Value/EBITDA
-3.79
Financial Highlights
Profitability and Income Statement
Profit Margin
-167.69%
Return on Assets (ttm)
-21.55%
Return on Equity (ttm)
-67.23%
Revenue (ttm)
27.46M
Net Income Avi to Common (ttm)
-46.05M
Diluted EPS (ttm)
-1.3000
Balance Sheet and Cash Flow
Total Cash (mrq)
67.74M
Total Debt/Equity (mrq)
70.74%
Levered Free Cash Flow (ttm)
-10.32M